These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 34344678)

  • 41. Fetuin-A and thyroxin binding globulin predict rituximab response in rheumatoid arthritis patients with insufficient response to anti-TNFα.
    Nguyen MVC; Courtier A; Adrait A; Defendi F; Couté Y; Baillet A; Guigue L; Gottenberg JE; Dumestre-Pérard C; Brun V; Gaudin P
    Clin Rheumatol; 2020 Sep; 39(9):2553-2562. PubMed ID: 32212002
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Number of active joints, not diagnosis, is the primary determinant of function and performance in early synovitis.
    Gerber LH; Furst G; Yarboro C; el-Gabalawy H
    Clin Exp Rheumatol; 2003; 21(5 Suppl 31):S65-70. PubMed ID: 14969053
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Real-world effectiveness and safety of rituximab in the treatment of rheumatoid arthritis: A single-center experience in Taiwan.
    Wang KC; Liao HT; Chen WS; Lai CC; Chou CT; Chen MH; Tsai CY
    Int J Rheum Dis; 2019 May; 22(5):860-868. PubMed ID: 30761753
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Improvement of large-joint ultrasonographic synovitis is delayed in patients with newly diagnosed rheumatoid arthritis: results of a 12-month clinical and ultrasonographic follow-up study of a local cohort.
    Harman H; Tekeoğlu İ; Takçı S; Kamanlı A; Nas K; Harman S
    Clin Rheumatol; 2015 Aug; 34(8):1367-74. PubMed ID: 25833144
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Low Risk of Hepatitis B Virus Reactivation in HBsAg-negative/Anti-HBc-positive Carriers Receiving Rituximab for Rheumatoid Arthritis: A Retrospective Multicenter Italian Study.
    Varisco V; Viganò M; Batticciotto A; Lampertico P; Marchesoni A; Gibertini P; Pellerito R; Rovera G; Caporali R; Todoerti M; Covelli M; Notarnicola A; Atzeni F; Sarzi-Puttini P
    J Rheumatol; 2016 May; 43(5):869-74. PubMed ID: 26879359
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Validity of 7-Joint Versus Simplified 12-Joint Ultrasonography Scoring Systems in Assessment of Rheumatoid Arthritis Activity.
    El-Gohary RM; Ahmed Mahmoud AA; Khalil A; El-Gendy H; Gado KH
    J Clin Rheumatol; 2019 Sep; 25(6):264-271. PubMed ID: 29965853
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Persistence of ultrasound synovitis in patients with rheumatoid arthritis fulfilling the DAS28 and/or the new ACR/EULAR RA remission definitions: results of an observational cohort study.
    Zufferey P; Möller B; Brulhart L; Tamborrini G; Scherer A; Finckh A; Ziswiler HR
    Joint Bone Spine; 2014 Oct; 81(5):426-32. PubMed ID: 24956986
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Three-dimensional volumetric ultrasound: a valid method for blinded assessment of response to therapy in rheumatoid arthritis.
    Naredo E; Acebes C; Brito E; de Agustín JJ; de Miguel E; Mayordomo L; Möller I; Moragues C; Rejón E; Rodriguez A; Uson J; Garrido J; Martínez-Hernández D;
    J Rheumatol; 2013 Mar; 40(3):253-60. PubMed ID: 23322469
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Assessing synovitis in the hands in patients with rheumatoid arthritis by ultrasound: an agreement study exploring the most inflammatory active side from two Norwegian trials.
    Terslev L; Christensen R; Aga AB; Sexton J; Haavardsholm EA; Hammer HB
    Arthritis Res Ther; 2019 Jul; 21(1):166. PubMed ID: 31277679
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Rituximab done: what's next in rheumatoid arthritis? A European observational longitudinal study assessing the effectiveness of biologics after rituximab treatment in rheumatoid arthritis.
    Walker UA; Jaeger VK; Chatzidionysiou K; Hetland ML; Hauge EM; Pavelka K; Nordström DC; Canhão H; Tomšič M; van Vollenhoven R; Gabay C
    Rheumatology (Oxford); 2016 Feb; 55(2):230-6. PubMed ID: 26316581
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Efficacy and Safety of Switching from Innovator Rituximab to Biosimilar CT-P10 Compared with Continued Treatment with CT-P10: Results of a 56-Week Open-Label Study in Patients with Rheumatoid Arthritis.
    Park W; Suh CH; Shim SC; Molina FFC; Jeka S; Medina-Rodriguez FG; Hrycaj P; Wiland P; Lee EY; Shesternya P; Kovalenko V; Myasoutova L; Stanislav M; Radominski S; Lim MJ; Choe JY; Lee SJ; Lee SY; Kim SH; Yoo DH
    BioDrugs; 2017 Aug; 31(4):369-377. PubMed ID: 28600696
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [The role of laboratory biomarkers in monitoring of rituximab biosimilar therapy (Acellbia, "BIOCAD") in patients with rheumatoid arthritis].
    Avdeeva AS; Cherkasova MV; Kusevich DA; Rybakova VV; Artyuhov AS; Dashinimaev EB; Chichasova NV; Nasonov EL
    Ter Arkh; 2019 May; 91(5):26-33. PubMed ID: 32598673
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Long-Term Efficacy and Safety of Biosimilar CT-P10 Versus Innovator Rituximab in Rheumatoid Arthritis: 48-Week Results from a Randomized Phase III Trial.
    Suh CH; Yoo DH; Berrocal Kasay A; Chalouhi El-Khouri E; Cons Molina FF; Shesternya P; Miranda P; Medina-Rodriguez FG; Wiland P; Jeka S; Chavez-Corrales J; Linde T; Hrycaj P; Abello-Banfi M; Hospodarskyy I; Jaworski J; Piotrowski M; Brzosko M; Krogulec M; Shevchuk S; Calvo A; Andersone D; Park W; Shim SC; Lee SJ; Lee SY
    BioDrugs; 2019 Feb; 33(1):79-91. PubMed ID: 30719632
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A combination of cellular biomarkers predicts failure to respond to rituximab in rheumatoid arthritis: a 24-week observational study.
    Stradner MH; Dejaco C; Brickmann K; Graninger WB; Brezinschek HP
    Arthritis Res Ther; 2016 Aug; 18(1):190. PubMed ID: 27558631
    [TBL] [Abstract][Full Text] [Related]  

  • 55. B cell repopulation kinetics after rituximab treatment in ANCA-associated vasculitides compared to rheumatoid arthritis, and connective tissue diseases: a longitudinal observational study on 120 patients.
    Thiel J; Rizzi M; Engesser M; Dufner AK; Troilo A; Lorenzetti R; Voll RE; Venhoff N
    Arthritis Res Ther; 2017 May; 19(1):101. PubMed ID: 28521808
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Indocyanine green-enhanced fluorescence optical imaging in patients with early and very early arthritis: a comparative study with magnetic resonance imaging.
    Werner SG; Langer HE; Schott P; Bahner M; Schwenke C; Lind-Albrecht G; Spiecker F; Kurtz B; Burmester GR; Backhaus M
    Arthritis Rheum; 2013 Dec; 65(12):3036-44. PubMed ID: 24022684
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Predictors of response of rituximab in rheumatoid arthritis by weighted gene co-expression network analysis.
    Zhang S; Li P; Wu P; Yang L; Liu X; Liu J; Zhang Y; Zeng J
    Clin Rheumatol; 2023 Feb; 42(2):529-538. PubMed ID: 36374432
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The efficiency of biologic therapy in a group of patients with rheumatoid arthritis.
    Gavrilă BI; Ciofu C; Stoica V; Panaitescu E
    J Med Life; 2015; 8(1):79-84. PubMed ID: 25914745
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Longitudinal power Doppler ultrasonographic assessment of joint inflammatory activity in early rheumatoid arthritis: predictive value in disease activity and radiologic progression.
    Naredo E; Collado P; Cruz A; Palop MJ; Cabero F; Richi P; Carmona L; Crespo M
    Arthritis Rheum; 2007 Feb; 57(1):116-24. PubMed ID: 17266071
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Power Doppler ultrasound monitoring of response to anti-tumour necrosis factor alpha treatment in patients with rheumatoid arthritis.
    Iagnocco A; Finucci A; Ceccarelli F; Perricone C; Iorgoveanu V; Valesini G
    Rheumatology (Oxford); 2015 Oct; 54(10):1890-6. PubMed ID: 26070937
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.